U
35.69
0.71 (2.03%)
| 前收盘价格 | 34.98 |
| 收盘价格 | 35.00 |
| 成交量 | 690,693 |
| 平均成交量 (3个月) | 808,190 |
| 市值 | 3,351,280,128 |
| 价格/销量 (P/S) | 5.77 |
| 股市价格/股市净资产 (P/B) | 13.13 |
| 52周波幅 | |
| 利润日期 | 30 Apr 2025 - 5 May 2025 |
| 营业毛利率 | -101.60% |
| 营业利益率 (TTM) | -74.16% |
| 稀释每股收益 (EPS TTM) | -6.29 |
| 季度收入增长率 (YOY) | 29.40% |
| 总债务/股东权益 (D/E MRQ) | 346.94% |
| 流动比率 (MRQ) | 2.37 |
| 营业现金流 (OCF TTM) | -414.19 M |
| 杠杆自由现金流 (LFCF TTM) | -207.49 M |
| 资产报酬率 (ROA TTM) | -22.37% |
| 股东权益报酬率 (ROE TTM) | -211.71% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Ultragenyx Pharmaceutical Inc. | 看涨 | 看涨 |
AIStockmoo 评分
0.3
| 分析师共识 | 5.0 |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | -2.0 |
| 平均 | 0.25 |
|
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 3.45% |
| 机构持股比例 | 97.24% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 136.00 (Canaccord Genuity, 281.06%) | 购买 |
| 中 | 117.00 (227.82%) | |
| 低 | 95.00 (HC Wainwright & Co., 166.18%) | 购买 |
| 平均值 | 116.20 (225.58%) | |
| 总计 | 5 购买 | |
| 平均价格@调整类型 | 41.48 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| JP Morgan | 27 Mar 2025 | 117.00 (227.82%) | 购买 | 38.89 |
| Piper Sandler | 17 Mar 2025 | 115.00 (222.22%) | 购买 | 39.64 |
| Cantor Fitzgerald | 26 Feb 2025 | 118.00 (230.62%) | 购买 | 41.62 |
| Canaccord Genuity | 18 Feb 2025 | 136.00 (281.06%) | 购买 | 43.62 |
| HC Wainwright & Co. | 18 Feb 2025 | 95.00 (166.18%) | 购买 | 43.62 |
| 14 Feb 2025 | 95.00 (166.18%) | 购买 | 42.49 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合